Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jan;4(1):155-62.
doi: 10.1016/j.nurt.2006.11.006.

Rufinamide

Santiago Arroyo  1
Affiliations
Review

Rufinamide

Santiago Arroyo. Neurotherapeutics. 2007 Jan.

Abstract

Rufinamide is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs. Rufinamide was profiled for anticonvulsant activity at the National Institutes of Health and showed broad-spectrum anticonvulsant properties at nontoxic doses in animal models. The principal mechanism of action of rufinamide is considered to be the modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Rufinamide provides an efficacious and well-tolerated treatment option for use as adjunctive therapy in patients with partial seizures and with Lennox-Gastaut syndrome (LGS). In LGS, rufinamide is effective in controlling multiple seizure types and in reducing the severity of the seizures. The most commonly observed (> or =10%) adverse experiences seen in association with rufinamide are headache, dizziness, fatigue, somnolence and nausea. Rufinamide is generally well tolerated, and its safety profile is well-established.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anonymous. Rufinamide: CGP 33101, E 2080, RUF 331, Xilep. Drugs R D 2005:6:249–252. - PubMed
    1. McLean MJ, Schmutz M, Pozza MF, Wamil AW. Effects of rufinamide on sodium-dependent action potential firing and sodium currents of rodent central neurons. Epilepsia. 2005;46(suppl 6):375–375.
    1. White S, Schmutz M, Pozza MF, et al. Rufinamide (CGP 33101): a broad-spectrum anticonvulsant with excellent tolerability profile in rodents. Epilepsia. 2005;46(suppl 6):373–373.
    1. Brunner LA, Harrigan EP, John VA, Powell ML. Pharmacokinetics of a new anticonvulsant (CGP 33101) in epileptic male patients and healthy male subjects after single ascending oral doses of 400–1200 mg. Am J Ther. 1994;1:215–220. doi: 10.1097/00045391-199410000-00008. - DOI - PubMed
    1. Cardot JM, Lecaillon JB, Czendlik C, et al. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharm Drug Dispos. 1998;19:259–262. doi: 10.1002/(SICI)1099-081X(199805)19:4<259::AID-BDD98>3.0.CO;2-V. - DOI - PubMed